UPPSALA, SWEDEN--(Marketwire - Nov. 4, 2009)
The World Health Organization recently declared H1N1 swine flu a global pandemic, resulting in the creation of rigorous vaccination programs worldwide. Children are among those considered particularly susceptible to contracting swine flu and are viewed as a top priority in receiving this vaccine.
Most H1N1 swine flu vaccines are prepared from virus grown in chicken's eggs, resulting in a vaccine that contains remnants of egg proteins. Egg allergy is one of the most common food allergies in infants and young children. The allergy can be mild or severe but oftentimes the severity level remains unidentified. Whether a child will be at low or high risk for a clinical reaction as a consequence of receiving this vaccine depends upon the severity of their allergy. As the number of swine flu vaccinations increases, the likelihood of clinical reactions occurring in children with an undetected severe egg allergy intensifies.
Following exposure to egg, children with this allergy may suffer from clinical reactions including rash, gastrointestinal and respiratory infections and even anaphylaxis. In a press release issued last month, the US Food and Drug Administration recommended against H1N1 influenza vaccination for people with severe or life-threatening allergies to chicken eggs. Determining the severity of egg allergy is essential to knowing whether or not a child can safely receive the H1N1 swine flu vaccine.
Phadia offers complete lab testing to accurately diagnose and identify severity level of egg allergy. ImmunoCAP, Phadia's precise, reliable allergy test that measures IgE antibodies, indicates clinical reaction to both egg white (f1) and ovomucoid (f233). The f1 test will help the physician to confirm or rule out an allergy to egg white. If an allergy to egg white is confirmed, the f233 follow-up test can be conducted to identify the severity of egg allergy and whether the child is at low or high risk for clinical reaction. Phadia is the only company to offer this important follow-up test.
Phadia's state-of-the-art ImmunoCAP allergy test system facilitates diagnosis in children with suspected egg allergy, and, upon diagnosis, determines the level of allergy severity. These comprehensive tests allow physicians to provide timely advice to parents and caregivers anxious to know whether or not their child should receive the H1N1 swine flu vaccine. Given the prevalence of the infection and urgency of the vaccination protocol now in place, Phadia's advanced allergy testing technology couldn't come at a more critical time. As the market leader in allergy testing, Phadia is committed to meeting the needs of the healthcare community.
Phadia develops, manufactures and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases. Besides strategic management, administration and business development, the international centre in Uppsala incorporates extensive research and development facilities, a state-of-the-art production plant and distribution system operating cost-effectively around the clock. In Freiburg, Germany, a second centre develops and supports diagnostic tests for autoimmune diseases. Some 98% of production is exported to more than 3,000 laboratories in 60 countries. Supplying seven out of ten allergy laboratory tests worldwide, the company has remained the world leader in its field for more than 25 years.
Except for historical information, all of the statements, expectations, and assumptions contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although Phadia attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based.
For more information, please contact Magnus Borres, M.D., Medical Director at email@example.com